Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Haemophilus influenzae | 18 | 2015 | 67 | 1.780 |
Why?
|
| Haemophilus Infections | 9 | 2015 | 29 | 0.910 |
Why?
|
| Bacterial Proteins | 12 | 2015 | 499 | 0.780 |
Why?
|
| Vaccines | 1 | 2023 | 37 | 0.770 |
Why?
|
| Heme | 12 | 2013 | 91 | 0.480 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2015 | 15 | 0.480 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 21 | 0.440 |
Why?
|
| Antigens, Viral | 1 | 2024 | 24 | 0.430 |
Why?
|
| Gene Expression Regulation, Bacterial | 6 | 2015 | 158 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 413 | 0.370 |
Why?
|
| Operon | 5 | 2013 | 40 | 0.350 |
Why?
|
| Biomarkers | 1 | 2024 | 787 | 0.330 |
Why?
|
| Cohort Studies | 4 | 2025 | 902 | 0.320 |
Why?
|
| Carrier Proteins | 6 | 2009 | 256 | 0.280 |
Why?
|
| Rural Population | 2 | 2025 | 140 | 0.250 |
Why?
|
| Humans | 21 | 2025 | 29078 | 0.250 |
Why?
|
| Medically Underserved Area | 1 | 2025 | 19 | 0.230 |
Why?
|
| Transformation, Bacterial | 1 | 2004 | 13 | 0.220 |
Why?
|
| Adult | 7 | 2025 | 8080 | 0.210 |
Why?
|
| Otitis Media | 5 | 2013 | 37 | 0.210 |
Why?
|
| Haptoglobins | 5 | 2006 | 22 | 0.210 |
Why?
|
| Iron | 6 | 2013 | 118 | 0.200 |
Why?
|
| Virulence | 6 | 2015 | 154 | 0.200 |
Why?
|
| Pediatric Obesity | 1 | 2024 | 79 | 0.190 |
Why?
|
| Lipoproteins | 3 | 2009 | 99 | 0.190 |
Why?
|
| Rats | 8 | 2015 | 1594 | 0.190 |
Why?
|
| Bacterial Outer Membrane Proteins | 4 | 2010 | 102 | 0.190 |
Why?
|
| Hemoglobins | 4 | 2006 | 118 | 0.180 |
Why?
|
| Genes, Bacterial | 4 | 2010 | 110 | 0.180 |
Why?
|
| Capacity Building | 1 | 2021 | 9 | 0.180 |
Why?
|
| Child Welfare | 1 | 2021 | 43 | 0.170 |
Why?
|
| Middle Aged | 4 | 2025 | 7458 | 0.170 |
Why?
|
| Prospective Studies | 3 | 2025 | 1286 | 0.160 |
Why?
|
| Female | 10 | 2025 | 15740 | 0.160 |
Why?
|
| Aged | 3 | 2025 | 5627 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 221 | 0.160 |
Why?
|
| Chinchilla | 4 | 2013 | 32 | 0.160 |
Why?
|
| Oklahoma | 1 | 2023 | 1062 | 0.150 |
Why?
|
| Male | 5 | 2025 | 14049 | 0.140 |
Why?
|
| Regulon | 3 | 2013 | 18 | 0.140 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 1522 | 0.130 |
Why?
|
| Indians, North American | 1 | 2021 | 545 | 0.130 |
Why?
|
| Animals | 13 | 2015 | 10756 | 0.130 |
Why?
|
| Burkholderia cepacia complex | 2 | 2006 | 4 | 0.120 |
Why?
|
| Mutation | 5 | 2012 | 873 | 0.120 |
Why?
|
| Transcytosis | 1 | 2015 | 4 | 0.120 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 36 | 0.120 |
Why?
|
| Bacterial Adhesion | 1 | 2015 | 28 | 0.120 |
Why?
|
| Child | 4 | 2025 | 2335 | 0.110 |
Why?
|
| Propensity Score | 1 | 2024 | 59 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2024 | 120 | 0.100 |
Why?
|
| Cell Line | 1 | 2015 | 701 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2015 | 267 | 0.100 |
Why?
|
| Ear, Middle | 1 | 2013 | 40 | 0.100 |
Why?
|
| United States | 2 | 2025 | 2252 | 0.100 |
Why?
|
| Sex Factors | 1 | 2025 | 473 | 0.100 |
Why?
|
| Genetic Techniques | 1 | 2012 | 12 | 0.100 |
Why?
|
| Microbial Viability | 1 | 2012 | 29 | 0.090 |
Why?
|
| Catalase | 2 | 2012 | 49 | 0.090 |
Why?
|
| Transcriptome | 1 | 2013 | 243 | 0.090 |
Why?
|
| Molecular Sequence Data | 4 | 2007 | 1057 | 0.090 |
Why?
|
| Siderophores | 1 | 2010 | 5 | 0.080 |
Why?
|
| Hemopexin | 2 | 2007 | 4 | 0.080 |
Why?
|
| Transcription, Genetic | 4 | 2013 | 405 | 0.080 |
Why?
|
| Risk Factors | 1 | 2025 | 2138 | 0.070 |
Why?
|
| Bacteremia | 4 | 2012 | 81 | 0.070 |
Why?
|
| Porphyrins | 1 | 2007 | 20 | 0.070 |
Why?
|
| Esterases | 1 | 2007 | 16 | 0.060 |
Why?
|
| NAD | 1 | 2007 | 104 | 0.060 |
Why?
|
| Virulence Factors | 1 | 2007 | 45 | 0.060 |
Why?
|
| DNA, Bacterial | 2 | 2004 | 312 | 0.060 |
Why?
|
| Haemophilus influenzae type b | 1 | 2006 | 3 | 0.060 |
Why?
|
| Ferritins | 1 | 2006 | 27 | 0.060 |
Why?
|
| Hemagglutinins | 1 | 2006 | 2 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2006 | 31 | 0.060 |
Why?
|
| Myoglobin | 1 | 2006 | 34 | 0.060 |
Why?
|
| Research Personnel | 1 | 2025 | 40 | 0.060 |
Why?
|
| Patient Selection | 1 | 2025 | 151 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 226 | 0.050 |
Why?
|
| Pregnancy | 4 | 2012 | 1261 | 0.050 |
Why?
|
| Trust | 1 | 2024 | 25 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 270 | 0.050 |
Why?
|
| Body Height | 1 | 2024 | 58 | 0.050 |
Why?
|
| Universities | 1 | 2024 | 125 | 0.050 |
Why?
|
| Base Sequence | 1 | 2004 | 589 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 50 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 55 | 0.050 |
Why?
|
| Body Weight | 1 | 2024 | 253 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2006 | 276 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 66 | 0.050 |
Why?
|
| Culture Media | 3 | 2007 | 99 | 0.050 |
Why?
|
| Animals, Newborn | 3 | 2009 | 183 | 0.050 |
Why?
|
| Vaccination | 1 | 2024 | 213 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2024 | 169 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2024 | 416 | 0.040 |
Why?
|
| Safety | 1 | 2021 | 33 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 481 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 194 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 554 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 188 | 0.040 |
Why?
|
| Multigene Family | 2 | 2010 | 51 | 0.040 |
Why?
|
| Phenotype | 2 | 2012 | 688 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2012 | 680 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 2651 | 0.030 |
Why?
|
| Burkholderia Infections | 2 | 2006 | 4 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 3233 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 697 | 0.030 |
Why?
|
| Peroxiredoxins | 1 | 2012 | 3 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2012 | 12 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 196 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 553 | 0.020 |
Why?
|
| Ferrichrome | 1 | 2010 | 2 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 128 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 39 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2009 | 65 | 0.020 |
Why?
|
| Genome, Bacterial | 1 | 2009 | 75 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 13 | 0.020 |
Why?
|
| Animals, Suckling | 1 | 2007 | 3 | 0.020 |
Why?
|
| Point Mutation | 1 | 2007 | 61 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 477 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 17 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2006 | 65 | 0.020 |
Why?
|
| Horses | 1 | 2006 | 37 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 40 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 788 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 389 | 0.020 |
Why?
|
| Hemagglutination Tests | 1 | 2006 | 6 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 82 | 0.020 |
Why?
|
| Burkholderia cepacia | 1 | 2006 | 5 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 242 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 15 | 0.010 |
Why?
|
| Cystic Fibrosis | 1 | 2006 | 34 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 79 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2006 | 112 | 0.010 |
Why?
|
| Environmental Microbiology | 1 | 2006 | 25 | 0.010 |
Why?
|
| Hemolysis | 1 | 2006 | 51 | 0.010 |
Why?
|
| Cytosol | 1 | 2005 | 49 | 0.010 |
Why?
|
| Meningitis, Haemophilus | 1 | 2004 | 3 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 740 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 381 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 385 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 490 | 0.010 |
Why?
|